(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
Celltrion USA is offering an 80 mg dose of Yuflyma (adalimumab-aaty), a high-concentration (100mg/ml) and citrate-free formulation of Humira (adalimumab) biosimilar, in the United States. Yuflyma is ...
Cigna’s pharmacy benefit manager Express Scripts will put “multiple" biosimilar versions of Abbvie’s expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s as a ...
July 27 (Reuters) - AbbVie (ABBV.N), opens new tab on Thursday trimmed its 2023 view for declining sales of its flagship arthritis drug Humira despite new competition, as favorable positions on ...
The biosimilars include Hyrimoz and an unbranded version of Humira from Swiss drugmaker Novartis' (NOVN.S), opens new tab Sandoz generics division, as well as German drugmaker Boehringer Ingelheim's ...
UnitedHealth Group’s pharmacy benefit manager Optum Rx Tuesday said it will put three less expensive “biosimilar” versions of Abbvie’s pricey rheumatoid arthritis drug Humira “in the same position as ...
As with other medications, Humira can interact with certain other drugs. It can also interact with some vaccines. An interaction occurs when one substance causes another substance to have a different ...
If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...
The arthritis drug Humira has been a blockbuster seller for more than two decades. Now some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback